NZ587824A - Novel method for the production of sulphonylpyrroles as hdac inhibitors - Google Patents

Novel method for the production of sulphonylpyrroles as hdac inhibitors

Info

Publication number
NZ587824A
NZ587824A NZ587824A NZ58782409A NZ587824A NZ 587824 A NZ587824 A NZ 587824A NZ 587824 A NZ587824 A NZ 587824A NZ 58782409 A NZ58782409 A NZ 58782409A NZ 587824 A NZ587824 A NZ 587824A
Authority
NZ
New Zealand
Prior art keywords
formula
compound
alkyl
alkoxy
group
Prior art date
Application number
NZ587824A
Other languages
English (en)
Inventor
Matthias Muller
Bernd Muller
Thomas Maier
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Ag filed Critical 4Sc Ag
Publication of NZ587824A publication Critical patent/NZ587824A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
NZ587824A 2008-03-12 2009-03-11 Novel method for the production of sulphonylpyrroles as hdac inhibitors NZ587824A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08004567A EP2100878A1 (en) 2008-03-12 2008-03-12 Novel method for the production of sulphonylpyrroles as HDAC inhibitors
PCT/EP2009/052870 WO2009112529A1 (en) 2008-03-12 2009-03-11 Novel method for the production of sulphonylpyrroles as hdac inhibitors

Publications (1)

Publication Number Publication Date
NZ587824A true NZ587824A (en) 2012-05-25

Family

ID=39639400

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ587824A NZ587824A (en) 2008-03-12 2009-03-11 Novel method for the production of sulphonylpyrroles as hdac inhibitors

Country Status (22)

Country Link
US (1) US8785659B2 (enExample)
EP (2) EP2100878A1 (enExample)
JP (1) JP5530939B2 (enExample)
KR (1) KR101571915B1 (enExample)
CN (1) CN101970404B (enExample)
AT (1) ATE519739T1 (enExample)
AU (1) AU2009224623C1 (enExample)
BR (1) BRPI0909752B8 (enExample)
CA (1) CA2719074C (enExample)
CY (1) CY1111994T1 (enExample)
DK (1) DK2265580T3 (enExample)
EA (1) EA017929B1 (enExample)
ES (1) ES2370592T3 (enExample)
IL (1) IL207995A (enExample)
MX (1) MX2010010015A (enExample)
NZ (1) NZ587824A (enExample)
PL (1) PL2265580T3 (enExample)
PT (1) PT2265580E (enExample)
SI (1) SI2265580T1 (enExample)
UA (1) UA102091C2 (enExample)
WO (1) WO2009112529A1 (enExample)
ZA (1) ZA201006422B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts
JP2019511544A (ja) 2016-04-14 2019-04-25 ４エスツェー アクチェンゲゼルシャフト アジア人患者におけるレスミノスタットの医薬用途
TW201912183A (zh) 2017-08-31 2019-04-01 德商４Ｓｃ製藥公司 Hdac抑制劑與抗代謝藥劑組合用於癌症治療

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960787A (en) 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
KR100236806B1 (ko) 1991-12-10 2000-01-15 시오노 요시히코 방향족 설폰아미드계 하이드록삼산 유도체
WO1996038418A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
EP1725528B1 (en) 2004-03-11 2013-05-29 4Sc Ag Sulphonylpyrroles as hdac inhibitors
EA201100689A1 (ru) 2005-03-15 2011-10-31 4Сц Аг N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
KR101314158B1 (ko) 2005-09-21 2013-10-04 4에스체 악티엔게젤샤프트 히스톤 탈아세틸 효소 억제제로서의 설포닐피롤 염산염
PL1928872T3 (pl) 2005-09-21 2012-08-31 4Sc Ag Nowe sulfonylopirole jako inhibitory HDAC

Also Published As

Publication number Publication date
UA102091C2 (ru) 2013-06-10
AU2009224623C1 (en) 2014-01-23
ZA201006422B (en) 2011-10-26
CA2719074C (en) 2017-01-17
CA2719074A1 (en) 2009-09-17
US8785659B2 (en) 2014-07-22
DK2265580T3 (da) 2011-10-31
KR101571915B1 (ko) 2015-11-25
CY1111994T1 (el) 2015-11-04
EP2265580B1 (en) 2011-08-10
HK1150319A1 (en) 2011-11-25
ES2370592T3 (es) 2011-12-20
BRPI0909752B8 (pt) 2021-05-25
EA201001270A1 (ru) 2011-04-29
KR20100121656A (ko) 2010-11-18
PL2265580T3 (pl) 2012-01-31
EP2100878A1 (en) 2009-09-16
US20110105568A1 (en) 2011-05-05
CN101970404A (zh) 2011-02-09
AU2009224623A1 (en) 2009-09-17
BRPI0909752B1 (pt) 2020-11-24
SI2265580T1 (sl) 2011-12-30
ATE519739T1 (de) 2011-08-15
IL207995A0 (en) 2010-12-30
BRPI0909752A2 (pt) 2015-10-06
WO2009112529A1 (en) 2009-09-17
EP2265580A1 (en) 2010-12-29
MX2010010015A (es) 2011-04-05
EA017929B1 (ru) 2013-04-30
JP2011513467A (ja) 2011-04-28
IL207995A (en) 2013-04-30
PT2265580E (pt) 2011-11-21
AU2009224623B2 (en) 2013-07-18
CN101970404B (zh) 2013-05-08
JP5530939B2 (ja) 2014-06-25

Similar Documents

Publication Publication Date Title
JP4405602B2 (ja) ヒストン脱アセチル化酵素阻害剤
AU684887B2 (en) Isoxazoline compounds as inhibitors of TNF release
CN108530310B (zh) 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
AU2009224710B2 (en) (E)-N-(2-amino-phenyl)-3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide salts
JP7026787B2 (ja) ヒストン脱アセチル化酵素１および／または２（ｈｄａｃ１－２）の選択的阻害剤としての新規なヘテロアリールアミド誘導体
EA012451B1 (ru) Новые амидозамещённые гидрокси-6-фенилфенантридины
JPH11335375A (ja) ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
KR20170095964A (ko) Hdac1/2 억제제로서 피페리딘 유도체
CN106573907B (zh) 喹啉衍生物及其用于神经退化性疾病的用途
EP2265580B1 (en) Novel method for the production of sulphonylpyrroles as hdac inhibitors
WO2013170757A1 (zh) 4-氨基喹唑啉异羟肟酸类化合物及作为抗肿瘤药物应用
CN108689937A (zh) 吲唑类化合物及其在制备ido抑制剂类药物上的用途
CN105801464A (zh) 吡咯酰胺类化合物及其制备方法与用途
EP4629984A1 (en) Development of potent dual hdac/brd4 inhibitors
KR20170067728A (ko) 아미노설포닐계 화합물, 이의 제조 방법 및 용도
HK1150319B (en) Novel method for the production of sulphonylpyrroles as hdac inhibitors
CN106496132B (zh) N-(4-取代苯基)-2-取代乙酰胺类化合物及其作为sirt2蛋白抑制剂的用途
WO2016107541A1 (zh) 吡咯酰胺类化合物及其制备方法与用途
CN111548286B (zh) 一种具有hdac3抑制活性的psa衍生物及其应用
KR20120109667A (ko) 열쇼크 단백질의 활성을 저해하는 신규 화합물
CN102249958B (zh) 苯甲酰氨类组蛋白去乙酰化酶抑制剂

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 MAR 2016 BY PAVIS EG

Effective date: 20130307

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2017 BY PAVIS EG

Effective date: 20160301

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2018 BY PAVIS GMBH

Effective date: 20170303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2019 BY PAVIS GMBH

Effective date: 20180228

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2020 BY PAVIS GMBH

Effective date: 20190226

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2021 BY PAVIS GMBH

Effective date: 20200211

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2022 BY PAVIS PAYMENTS GMBH

Effective date: 20210304

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2023 BY PAVIS PAYMENT GMBH

Effective date: 20220303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2024 BY PAVIS PAYMENTS GMBH

Effective date: 20230224

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2025 BY PAVIS PAYMENT GMBH

Effective date: 20240224

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2026 BY PAVIS PAYMENT GMBH

Effective date: 20250228